Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305911 · ClinicalTrials.gov registry record · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
A Phase 2 study of Heart Attack and Enlarged Heart, sponsored by Minneapolis Heart Institute Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT05305911: Recruiting Phase 2 study of Heart Attack and Enlarged Heart, sponsored by Minneapolis Heart Institute Foundation.
NCT05305911 is a Phase 2 study of Heart Attack and Enlarged Heart that is actively recruiting participants, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 81 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05305911, a Phase 2 study of Heart Attack and Enlarged Heart, is actively recruiting participants, sponsored by Minneapolis Heart Institute Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Primary Outcome
Change in LVESVI at 6 months as measured by MRI.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SGLT-2 inhibitors
Study Locations (1)
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT05305911 shows while recruiting
NCT05305911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (39% lower).
The record links to 2 conditions, with Heart Attack appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05305911 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05305911 about?
NCT05305911 is a clinical study titled "Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI". The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one c...
What is the current status of trial NCT05305911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2022-08-03. Estimated completion is 2028-12.
What conditions does trial NCT05305911 study?
This clinical trial studies the following conditions: Heart Attack, Enlarged Heart.
What interventions are being tested in trial NCT05305911?
The interventions under investigation include: Placebo (DRUG), SGLT-2 inhibitors (DRUG).
Who is sponsoring clinical trial NCT05305911?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05305911 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Attack
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05305911's enrollment target sits among peer trials
81 834th of 2000 higher than 1,160 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05626621 · 81 participants · Phase 4
Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI